BioLite, Inc. formed an alliance with American BriVision Corporation (ABVC) to co-develop the US market for its new drugs

including combination therapy for Triple-negative breast cancer (TNBC), cancer combination therapy,

Hematology-Chronic Lymphocytic Leukemia (HCLL), Attention Deficit Hyperactivity Disorder(ADHD) and Major Depressive Disorder.

 

 

For the cancer combination therapy project, BioLite, Inc. has initiated the co-operation with an oversea partner, and is also technically

supported by a US renowned cancer center. These partners also came to support the BioLite-sponsored

International Symposium on Hematology & Oncology held in Oct., 2015, Taipei.